Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting ...Middle East

SKYLIGHT 4™ study results demonstrate the 52-week safety and tolerability of fezolinetant 30 mg and 45 mg once daily Pooled analyses will also be presented from SKYLIGHT 1™ and SKYLIGHT 2™ studies of fezolinetant, Astellas' investigational nonhormonal treatment for vasomotor symptoms...

Hence then, the article about astellas to present findings from phase 3 long term safety study of fezolinetant in oral session at the north american menopause society 2022 annual meeting was published today ( Wednesday 12/10/2022 - 07:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting )

Also on site :

• Sydney Sweeney Goes Viral for Racy New Ad Showing Off Nude Appearance: ‘She’s Got the Whole Internet Malfunctioning… AGAIN’
• Inter Miami vs Chicago Fire: Match Time, Channels and How to Watch
• Dolly Parton Filmed Her SongTeller Welcome Before She Left Us — On September 29 She’ll Still Be in Nashville to Greet You